CL2025003919A1 - Proteínas de unión a receptor de linfotoxina beta agonistas. - Google Patents

Proteínas de unión a receptor de linfotoxina beta agonistas.

Info

Publication number
CL2025003919A1
CL2025003919A1 CL2025003919A CL2025003919A CL2025003919A1 CL 2025003919 A1 CL2025003919 A1 CL 2025003919A1 CL 2025003919 A CL2025003919 A CL 2025003919A CL 2025003919 A CL2025003919 A CL 2025003919A CL 2025003919 A1 CL2025003919 A1 CL 2025003919A1
Authority
CL
Chile
Prior art keywords
binding proteins
ltβr
beta agonists
lymphotoxin receptor
proteins beta
Prior art date
Application number
CL2025003919A
Other languages
English (en)
Spanish (es)
Inventor
Garces Fernando
Nevin Foltz Ian
Zhang Jun
Benjamin Case Ryan
NOUBADE Rajkumar
Yu WANG Hong
GONG Danyang
LAI Chin-Wen
Elaine Tinberg Christine
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2025003919A1 publication Critical patent/CL2025003919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2025003919A 2023-06-12 2025-12-12 Proteínas de unión a receptor de linfotoxina beta agonistas. CL2025003919A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12

Publications (1)

Publication Number Publication Date
CL2025003919A1 true CL2025003919A1 (es) 2026-01-23

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003919A CL2025003919A1 (es) 2023-06-12 2025-12-12 Proteínas de unión a receptor de linfotoxina beta agonistas.

Country Status (14)

Country Link
EP (1) EP4724490A2 (fr)
KR (1) KR20260025131A (fr)
CN (1) CN121399157A (fr)
AR (1) AR132931A1 (fr)
AU (1) AU2024305352A1 (fr)
CL (1) CL2025003919A1 (fr)
CO (1) CO2025018800A2 (fr)
IL (1) IL325097A (fr)
JO (1) JOP20250305A1 (fr)
MX (1) MX2025015224A (fr)
PE (1) PE20260306A1 (fr)
TW (1) TW202506733A (fr)
UY (1) UY40783A (fr)
WO (1) WO2024258870A2 (fr)

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AU2006265936A1 (en) 2005-07-01 2007-01-11 Medimmune, Llc An integrated approach for generating multidomain protein therapeutics
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CA2682390A1 (fr) 2007-04-17 2008-10-30 Imclone Llc Inhibiteurs specifiques de pdgfr.beta.
ME02345B (fr) 2007-07-17 2016-08-31 Squibb & Sons Llc Anticorps monoclonaux contre le glypicane-3
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
AU2008337517B2 (en) 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EP2236517A1 (fr) 2009-03-31 2010-10-06 Takara Bio, Inc. Anticorps monoclonal à fragment anti-fibronectine
AU2010249531A1 (en) 2009-05-21 2011-12-15 Tamarisk Technologies, L.L.C. Alginate-based building materials
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
KR101528013B1 (ko) 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
WO2011130580A1 (fr) 2010-04-15 2011-10-20 Alper Biotech, Llc Anticorps monoclonaux contre antigènes her2 et leurs utilisations
EP2563816B1 (fr) 2010-04-27 2014-11-12 National Research Council of Canada Anticorps à domaine unique anti-icam-1 et leurs utilisations
WO2011139375A1 (fr) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
CA2800488A1 (fr) 2010-05-26 2011-12-01 Regents Of The University Of Minnesota Anticorps anti-cd133 a fragment variable a chaine simple et ses utilisations
EP2576621B1 (fr) 2010-05-27 2019-04-10 Genmab A/S Anticorps monoclonaux contre her2
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
EP2595657A4 (fr) 2010-07-22 2015-09-23 Univ California Anticorps-antigènes antitumoraux et méthodes d'utilisation correspondantes
JP5883443B2 (ja) 2010-07-22 2016-03-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規の抗原結合タンパク質
WO2012163771A1 (fr) 2011-06-03 2012-12-06 Ct Atlantic Ltd. Anticorps se liant à mage a3
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
EP2548891A1 (fr) 2011-07-18 2013-01-23 Universiteit Maastricht Anticorps monoclonal humain contre la subunité gamma du récepteur de l'acétylcholine pour une utilisation dans le traitement du rhabdomyosarcome
CA2890483A1 (fr) 2012-11-09 2014-05-15 Robert ARCH Anticorps specifiques du facteur de croissance b derive des plaquettes, leurs compositions et leurs utilisations
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
CN117843785A (zh) 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
LT3030581T (lt) 2013-08-07 2021-05-25 Affimed Gmbh Antikūno surišimo vietos specifiškos egfrviii
JP6632984B2 (ja) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
KR20160145119A (ko) 2014-05-14 2016-12-19 에프. 호프만-라 로슈 아게 Her1의 베타-헤어핀에 결합하는 her1 항원 결합 단백질
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
EP4245376A3 (fr) 2014-10-14 2023-12-13 Novartis AG Molécules d'anticorps de pd-l1 et leurs utilisations
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
WO2016154623A2 (fr) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps monoclonaux anti-cd133 et compositions et méthodes associées
EP4019552A1 (fr) 2015-06-10 2022-06-29 National Research Council of Canada Anticorps spécifiques de l'anhydrase carbonique ix et leurs utilisations
HK1248255A1 (zh) 2015-06-24 2018-10-12 优瑞科生物技术公司 靶向ny-eso-1肽/mhc复合物的构建体及其用途
MA46046A (fr) 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
EP3684818A2 (fr) 2017-09-21 2020-07-29 UMC Utrecht Holding B.V. Anticorps anti-gd2 pour le traitement du neuroblastome
CA3080120C (fr) 2017-10-27 2023-11-21 New York University Anticorps anti-galectine-9 et leurs utilisations
MX2020006119A (es) 2017-12-21 2020-08-24 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1.
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
WO2020003210A1 (fr) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anticorps anti-l1cam et leurs utilisations
WO2020025792A1 (fr) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Constructions d'anticorps pour cldn18.2 et cd3
CA3116314A1 (fr) 2018-10-15 2020-04-23 Board Of Regents, The University Of Texas System Anticorps monoclonaux diriges contre la dickkopf3 humaine et leurs utilisations
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations

Also Published As

Publication number Publication date
CN121399157A (zh) 2026-01-23
AR132931A1 (es) 2025-08-13
IL325097A (en) 2026-02-01
JOP20250305A1 (ar) 2025-12-11
AU2024305352A1 (en) 2025-12-04
WO2024258870A2 (fr) 2024-12-19
EP4724490A2 (fr) 2026-04-15
PE20260306A1 (es) 2026-02-11
MX2025015224A (es) 2026-02-03
KR20260025131A (ko) 2026-02-23
CO2025018800A2 (es) 2026-03-26
UY40783A (es) 2024-12-31
WO2024258870A8 (fr) 2025-12-11
TW202506733A (zh) 2025-02-16

Similar Documents

Publication Publication Date Title
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
CL2024002235A1 (es) Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso.
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
MX2020008184A (es) Receptores de antigeno quimericos dirigidos a cd70.
MX2021001510A (es) Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EA202091420A1 (ru) Радиоактивное мечение полипептидов
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
MY199751A (en) Anti-igf-i receptor antibody
MX2017011534A (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
UY37568A (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr)
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
MX2021012160A (es) Anticuerpos antiintegrina y usos de los mismos.